US NIH Resumes Indian Trials But Keen On 'Elaborations' Of Rules
This article was originally published in SRA
Executive Summary
More than two years after it cut back on Indian clinical trials, the US National Institutes of Health, the largest public funder of biomedical research in the world, appears to have recommenced activity in the area, albeit on a cautious note.
You may also be interested in...
India Tweaks More Trial Rules But Can It Change The Narrative?
India has tweaked another set of trial rules including one that capped the number of trials per investigator as it seeks to clear the logjam of regulatory requirements that has been stifling the clinical research segment in the country. Much though could depend on actual implementation and it remains to be seen if such measures can alter the course of sector.
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.